Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
P.3.16 Impulsivity in bipolar disorder: a randomized clinical trial of adjunctive oxcarbazepine — Adriane Ribeiro Rosa (2009) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
P.3.16 Impulsivity in bipolar disorder: a randomized clinical trial of adjunctive oxcarbazepine
Shared by
Eduard Vieta
P.3.16 Impulsivity in bipolar disorder: a randomized clinical trial of adjunctive oxcarbazepine
Article
2009
en
Authors
+1 more
AR
Adriane Ribeiro Rosa
NC
Nelly M. Cruz
MC
Mercé Comes
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2008
A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder
Eduard Vieta
,
Núria Cruz
,
Javier García‐Campayo
,
Rosario de Arce
,
José Manuel Crespo
,
Vicenç Vallès
,
Josefina Pérez‐Blanco
,
Ernesto Roca
,
J.M. Olivares
,
Ángel Moríñigo
,
Raul Fernández-Villamor
,
Mercé Comes
Article
2023
Mindfulness, Attention, and Impulsivity in Bipolar Disorder
Natalia E. Fares‐Otero
,
Brisa Solé
,
Sara Martin‐Parra
,
Flavia Piazza
,
José Sánchez‐Moreno
,
Eduard Vieta
,
Anabel Martínez‐Arán
Article
2011
Impulsivity and functional impairment in bipolar disorder
Esther Jiménez
,
Bárbara Arias
,
Pere Castellví
,
José Manuel Goikolea
,
Adriane Ribeiro Rosa
,
Lourdes Fañanás
,
Eduard Vieta
,
Antoni Benabarre
Article
2006
A Double-Blind, Randomized, Placebo-Controlled, Prophylaxis Study of Adjunctive Gabapentin for Bipolar Disorder
Eduard Vieta
,
José Manuel Goikolea
,
Anabel Martínez‐Arán
,
Mercé Comes
,
K. Verger
,
Xavier Masramón
,
José Sánchez‐Moreno
,
Francesc Colom
Article
2025
Intermittent Theta Burst Stimulation With Adjunctive <scp>D</scp>-Cycloserine for Obsessive-Compulsive Disorder: A Randomized Clinical Trial
Alexander McGirr
,
Jaeden Cole
,
Scott Burton Patten
,
Beverly Adams
Discussion(0)
No comments yet. Be the first to comment.